Sensus Healthcare’s SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients
BOCA RATON, Fla, May 17, 2023 — Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment, is announcing that its superficial radiation therapy SRT-100 system has shown promising results treating Cutaneous Mast Cell Tumors (MCTs) in pets. This new limited study, just published in the […]
Sensus Healthcare Reports First Quarter 2023 Financial Results
Lower demand for SRT systems reflects the impact of inflation on dermatologists’ cash flow from fewer elective aesthetic procedures and higher operating costs Sensus expects to ship more than 60 SRT units during 2023 and return to profitability in the second half of the year Conference call begins at 4:30 p.m. Eastern time today BOCA […]
Chinese Health Authority Renews License for Sensus Healthcare’s SRT-100™ for Five More Years
Third Renewal for System to Treat Non-melanoma Skin Cancer and Keloids Across Greater China BOCA RATON, Fla., Oct. 12, 2021 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the Chinese Health Authority has renewed Sensus’ license to […]
Holy Name Medical Center in Teaneck, New Jersey Acquires Sensus Healthcare’s Low-dose Radiation Therapy System to Treat Pneumonia in COVID-19 Patients
BOCA RATON, Fla., Jan. 06, 2021 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced Holy Name Medical Center in Teaneck, New Jersey has acquired a Sensus low-dose radiation therapy system for the treatment of pneumonia in COVID-19 […]
Sensus Healthcare Announces Study Showing Single Low Dose of Superficial Radiation Therapy Prevents Keloid Recurrence Following Surgical Excision
Prospective study published in Journal of the American Academy of Dermatology BOCA RATON, Dec. 01, 2020 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the publication of a prospective clinical study showing that a single low dose of […]
Sensus Healthcare Announces Publication of Study Showing Use of Superficial Radiation Therapy Post-Keloidectomy Prevents Keloid Recurrence
Keloid recurrence rate of 10.4% at 12 months for patients treated with SRT following keloidectomy compares with more than 80% with surgical excision alone Retrospective study published in Journal of Clinical and Aesthetic Dermatology BOCA RATON, Fla., Oct. 22, 2020 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, […]
American Society of Radiologic Technologists Approves Sensus Healthcare’s SRT Systems for Continuing Education Units
Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems BOCA RATON, Fla, Aug. 05, 2020 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, and the leading provider of superficial radiotherapy […]
Sensus Healthcare Announces Publication of Research on Long-term Efficacy and Safety of Superficial Radiation Therapy in Journal of Drugs in Dermatology
Retrospective registry study showed a 98.9% non-recurrence rate after 85 months in subjects with non-melanoma skin cancer treated with SRT BOCA RATON, Fla. , March 03, 2020 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that results […]
Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radiation Therapy to Treat Non-Melanoma Skin Cancers and Keloids
Published in The Journal of Clinical and Aesthetic Dermatology, Consensus was Reached that SRT is Safe, and Effective in Treating SCC and BCC and Should be Considered as the First-Line Form of Radiation Treatment. BOCA RATON, Fla., Feb. 14, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment […]
Sensus Healthcare Announces Low 3% Keloid Recurrence in Multicenter Case Series of 297 Patients Treated with Superficial Radiation Therapy
SRT-100, a Low-energy X-ray Technology, Used at Site of Keloidectomy Treatment BOCA RATON, Fla., Dec. 6, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announced today positive results of a multicenter case series of […]
